However, the criteria for determining HER2 amplification/overexpression in intrahepatic cholangiocarcinoma (ICC) are not well-established, as they primarily rely on criteria developed for breast and gastric cancers (Schalper et al. 2014). The gene discussed is ERBB2; the disease is gastric cancer.